Deal Lab · Buyout model 1.0
CVS Health Corporation Buyout Model
The buyout model of CVS Health Corporation on its published figures, in US dollars.
Inputs Missing
The model of this company does not run on its published figures, which leave out the following. No figure stands in for a missing input.
- Payables: no payables are published at the end of the base period.
Inputs and Their Documents
Published figures of the last 4 quarters to Q2 FY2026, each with the documents it comes from.
| Input | Value | Method | Documents |
|---|---|---|---|
| Adjusted EBITDA | $15.9bn est. | Adjusted EBITDA of the company page | 10-Q 2025-09, 10-Q 2025-06, 10-K 2025-12, 10-Q 2026-03, 10-Q 2026-06 |
| Share-based pay | $715m | Share-based pay that adjusted EBITDA adds back | 10-Q 2025-06, 10-Q 2025-09, 10-K 2025-12, 10-Q 2026-03, 10-Q 2026-06 |
| EBITDA after share-based pay | $15.2bn est. | Adjusted EBITDA less share-based pay | 10-Q 2025-09, 10-Q 2025-06, 10-K 2025-12, 10-Q 2026-03, 10-Q 2026-06 |
| Depreciation and amortisation | $4.5bn | Depreciation and amortisation of adjusted EBITDA | 10-Q 2025-09, 10-K 2025-12, 10-Q 2026-03, 10-Q 2026-06 |
| Revenue | $415bn | Revenue of the base period | 10-Q 2025-09, 10-K 2025-12, 10-Q 2026-03, 10-Q 2026-06 |
| Operating lease cost | $2.4bn est. | Operating lease cost | 10-K 2025-12 |
| Borrowings | $61.4bn | Total debt less lease liabilities | 10-Q 2026-06 |
| Lease liabilities | $14.9bn | Lease liabilities | 10-Q 2026-06 |
| Cash and short-term investments | $14.0bn | Cash and short-term investments | 10-Q 2026-06 |
| Non-controlling interests | $197m | Non-controlling interests | 10-Q 2026-06 |
| Receivables | $40.3bn | Receivables | 10-Q 2026-06 |
| Inventories | $17.6bn | Inventories | 10-Q 2026-06 |
| Capital expenditure | $2.8bn | Capital expenditure of the latest fiscal year | 10-K 2025-12 |
Deal Lab computes arithmetic on published figures and on the assumptions of the user. It values no company, recommends no transaction and forecasts no result.